Dose escalation/expansion trial with BYON4228 alone and in combination in metastatic solid tumors

2024-517952-37-00 Protocol BYON4228.002 Phase I and Phase II (Integrated) - Other Ongoing, recruitment ended

Start 22 May 2025 · Status Ongoing, recruitment ended · 2 EU/EEA countries · 6 sites · Protocol BYON4228.002

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruitment ended
Participants planned 100
Countries 2
Sites 6

Locally advanced or metastatic cancer (Solid tumors)

Key facts

Sponsor
Byondis B.V.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
22 May 2025 → ongoing
Decision date (initial)
2025-05-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Locally advanced or metastatic cancer (Solid tumors)

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Byondis B.V.

Sponsor organisation
Byondis B.V.
Address
Microweg 22
City
Nijmegen
Postcode
6545 CM
Country
Netherlands

Scientific contact point

Organisation
Byondis B.V.
Contact name
Clinical Development

Public contact point

Organisation
Byondis B.V.
Contact name
Clinical Development

Locations

2 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 30 2
Spain Ongoing, recruitment ended 33 4
Rest of world
United Kingdom
37

Investigational sites

Belgium

2 sites · Ended
UZ Leuven
Medical Oncology, Herestraat 49, 3000, Leuven
Institut Jules Bordet
Medical Oncology, Mijlenmeersstraat 90, 1070, Anderlecht

Spain

4 sites · Ongoing, recruitment ended
Institut Catala D'oncologia
Medical Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Hm Sanchinarro
Medical Oncology, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-06-13 2026-03-11 2025-08-18 2025-10-06
Spain 2025-05-22 2025-06-02 2025-10-06

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-01-27 Spain Acceptable
2025-04-30
2025-04-30
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-17 Spain Acceptable
2025-04-30
2025-06-17
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-04-10 Spain Acceptable
2025-04-30
2026-04-10